Company Overview and News

1
Stocks soar despite escalation of U.S.-China trade war

2018-09-18 japantimes.co.jp
Stocks extended gains substantially Tuesday despite the announcement of a third round of extra U.S. tariffs on Chinese exports.
MRAAF AAPL MRAAY

1
Nikkei has best gain in 5 weeks, insurers rise and US tariffs shrugged off

2018-09-18 reuters
TOKYO, Sept 18 (Reuters) - Japan’s Nikkei rallied on Tuesday to its highest close since Feb. 1, led by insurers thanks to rising U.S. Treasury yields, though electronic suppliers underperformed as traders weighted the impact of new U.S. tariffs on Chinese goods.
KYO MRAAF AAPL MRAAY 8750

1
Nikkei rallies as insurers gain on rising US Treasury yields

2018-09-18 thehindubusinessline
Japan's Nikkei rallied on Tuesday led by gains for insurers thanks to rising US Treasury yields, though electronic suppliers underperformed as traders considered the implications of fresh US tariffs on Chinese goods.
KYO MRAAF AAPL MRAAY 8750

 
Nikkei gains, insurers up; LDP election hopes temper Trump's tariff move

2018-09-18 reuters
TOKYO, Sept 18 (Reuters) - Japan’s Nikkei rallied on Tuesday led by gains for insurers thanks to rising U.S. Treasury yields, though electronic suppliers underperformed as traders considered the implications of fresh U.S. tariffs on Chinese goods.
KYO MRAAF MRAAY 8750

 
Asia Markets: Asian markets continue to rise, as Nikkei nears 7-month high

2018-09-14 marketwatch
Asian markets rose in early trading Friday although trade tensions between the U.S. and China lingered. While China said it welcomed an invitation for new trade talks with the U.S., an editorial in a state-run newspaper Friday warned that China would not cave to pressure.
MRAAF MRAAY

3
Nikkei soars as Sino-U.S. trade talk hopes lift stocks sensitive to China demand

2018-09-13 reuters
TOKYO, Sept 13 (Reuters) - Japan’s Nikkei rallied to near two-week highs on Thursday as news of a proposed fresh round of trade talks between China and the United States lifted risk appetite, triggering buying in stocks which are exposed to Chinese demand.
KMTUF ADTTF TTDKF MU MRAAF MRAAY 8035 TOELF ATEYY TOELY

3
Nikkei rises to near 2-week highs on Sino-U.S. trade talk hopes

2018-09-13 theedgemarkets
TOKYO (Sept 13): Japan's Nikkei rallied to near two-week highs on Thursday morning after news of a fresh round of trade talks between China and the United States lifted risk appetite, triggering buying in stocks which are sensitive to demand in China.
KMTUF ADTTF TTDKF MU MRAAF MRAAY 8035 TOELF ATEYY TOELY

3
Nikkei rises to near 2-week highs on Sino-U.S. trade talk hopes

2018-09-13 reuters
TOKYO, Sept 13 (Reuters) - Japan’s Nikkei rallied to near two-week highs on Thursday morning after news of a fresh round of trade talks between China and the United States lifted risk appetite, triggering buying in stocks which are sensitive to demand in China.
KMTUF ADTTF TTDKF MU MRAAF MRAAY 8035 TOELF ATEYY TOELY

 
Typhoon Jebi makes landfall in Japan, strongest in 25 years

2018-09-04 bworldonline
Typhoon Jebi made landfall in western Japan on Tuesday, the strongest tropical cyclone to come ashore in 25 years, and has picked up speed as it bears down on one of the nation’s most densely populated areas.
9021 PCRFY JAPSY TM TYT MRAAY TOYOF KYO MRAAF ALNPY 7203 ALNPF 9202

 
Typhoon Jebi makes landfall in Japan, strongest in 25 years

2018-09-04 theedgemarkets
(Sept 4): Typhoon Jebi made landfall in western Japan on Tuesday, the strongest tropical cyclone to come ashore in Japan in 25 years, and has picked up speed as it bears down on one of Japan’s most densely populated areas.
9021 PCRFY JAPSY TM TYT MRAAY TOYOF KYO MRAAF ALNPY 7203 ALNPF 9202

 
Nikkei edges down to 22,192 on receding U.S.-China trade worries

2018-08-16 japantimes.co.jp
The key Nikkei average closed marginally lower Thursday after cutting most of its early loss thanks to receding worries about U.S.-China trade friction.
5406 KBSTF KBSTY MRAAF MRAAY

 
Tokyo stocks jump on Wall Street gain, weaker yen

2018-08-01 japantimes.co.jp
Stocks rose sharply on the Tokyo Stock Exchange on Wednesday, with investor sentiment bolstered by an overnight rise in U.S. equities and a weaker yen.
KYO MRAAF 5411 MRAAY JFEEF

 
Tokyo stocks rise further on brisk U.S. and European markets

2018-07-25 japantimes.co.jp
Stocks extended gains on the Tokyo Stock Exchange on Wednesday, with investor sentiment brightened by overnight rises in U.S. and European equities.
6755 MRAAF FGELF MRAAY

2
Nikkei falls sharply on stronger yen

2018-07-23 japantimes.co.jp
The Nikkei 225 gave up 300.89 points, or 1.33 percent, to end at 22,396.99. The key market gauge sagged 66.80 points Friday.
TM SMFG TYT MRAAY SFTBF TOYOF SMFNF TOELY 8316 MRAAF 8306 7203 MUFG 9984 8750 8035 TOELF MBFJF SFTBY MTU

 
Japanese stocks stumble, spooked by yuan's fall

2018-07-20 reuters
TOKYO, July 20 (Reuters) - Japanese stocks dropped on Friday as an extended decline in the Chinese yuan rekindled worries about the stability of the Chinese economy which faces rising risks from a major trade conflict with the United States
5406 KBSTF KBSTY MRAAF MRAAY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 006610403